创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

白细胞介素-2诱导型酪氨酸激酶抑制剂研究进展

Research Progress of Interleukin-2 Inducible Tyrosine Kinase Inhibitors

  • 摘要: 白细胞介素-2诱导型酪氨酸激酶(ITK)属于在肝癌细胞中表达的酪氨酸激酶(Tec)家族,主要在T细胞中表达。ITK通过参与T细胞受体(TCR)信号传导,在下游发挥作用,控制促炎细胞因子的表达。研究表明,ITK与自身免疫性疾病的发病有关。通过使用ITK抑制剂,可以使免疫性炎症得到抑制。通过对ITK的结构、在T细胞中的信号通路及其在炎症中的作用进行介绍并综述ITK抑制剂的研究进展,旨在为ITK抑制剂的开发提供参考。

     

    Abstract: Interleukin-2 inducible tyrosine kinase (ITK) belongs to the tyrosine kinase family (Tec) expressed in hepatocellular carcinoma and is mainly expressed in T cells. ITK is involved in T-cell receptor (TCR) signaling, functions downstream and controls the expression of proinflammatory cytokines. Studies have shown that ITK is associated with the pathogenesis of autoimmune diseases. Immune inflammation can be suppressed by the use of ITK inhibitors. This paper introduces the structure of ITK, its signaling pathway in T cells and its role in inflammation, and reviews the research progress of ITK inhibitors, aiming to provide reference for the development of ITK inhibitors.

     

/

返回文章
返回